Pfizer Adjusts Earnings Projections Following Robust Second Quarter Results

Tuesday, 30 July 2024, 13:33
Pfizer has significantly revised its 2024 earnings forecast upwards, exceeding Wall Street's expectations. Initially, the company started the year with a less optimistic outlook that disappointed investors. However, strong sales growth from non-COVID medications, particularly the blood thinner Eliquis, contributed to better-than-anticipated results in the second quarter, with adjusted earnings reaching 60 cents per share. This positive shift in forecasts demonstrates Pfizer's resilience and adaptability in the pharmaceutical market.
Yahoo Finance
Pfizer Adjusts Earnings Projections Following Robust Second Quarter Results

Pfizer's Strong Earnings Performance

Pfizer is making headlines as it adjusts its earnings forecast for 2024 following a strong performance in the second quarter. After an initially disappointing forecast, the drugmaker has now projected earnings that are well above analyst expectations.

Sales Growth of Non-COVID Drugs

  • Record sales growth for non-COVID related drugs
  • Significant contributions from the blood thinner Eliquis
  • Adjusted earnings reached 60 cents per share in Q2

This robust growth highlights Pfizer's ability to pivot and thrive even amid challenges in the pharmaceutical landscape.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe